NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00344526,Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis,https://clinicaltrials.gov/study/NCT00344526,,COMPLETED,"AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem organ failure and death. The prognosis for AL amyloidosis with conventional treatment remains poor, Autologous stem cell transplantation (ASCT) for AL amyloidosis produces high hematologic and organ responses. However, treatment-related mortality remains high and reported series are subject to selection bias.",NO,Primary Systemic Amyloidosis (AL),DRUG: Melphalan|DRUG: Dexamethasone|PROCEDURE: Autologous stem cell transplantation,survival,hematologic responses|clinical responses,,"University Hospital, Limoges","Ministry of Health, France",ALL,"ADULT, OLDER_ADULT",PHASE3,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,I00001,2000-01,,2006-06,2006-06-26,,2007-06-28,"Service des Maladies du Sang, Lille, France|Service d'Hématologie et de Thérapie cellulaire, Limoges, France|Service d'hématologie clinique, Nantes, France|Service d'hématologie Clinique, Groupe Hospitalier Pitié-Salpétrière, Paris, France|Service d'hématologie clinique, Hôpital Necker, Paris, France|Service d'immuno-hématologie, Hôpital Saint-Louis, Paris, France|Service d'hématologie, Toulouse, France|Hématologie Clinique, Tours, France",
